E-LIB Suche - Ergebnisse für: Weiland, O.

1

Temperature and Performance Inhomogeneities in PEM Electrol..:

Krenz, T. ; Weiland, O. ; Trinke, P....
Journal of The Electrochemical Society. 170 (2023) 4 - p. 044508 , 2023

Link: https://doi.org/10.1149/..

2

PIN20 SOCIETAL PRODUCTIVITY GAINS FROM NEW THERAPIES IN HEP..:

Löfvendahl, S. ; Brådvik, G. ; Weiland, O..
Value in Health. 23 (2020) - p. S172 , 2020

Link: https://doi.org/10.1016/..

3

Concomitant drug use in patients with chronic hepatitis C a..:

Söderholm, J. ; Weiland, O. ; Brolund, A....
Journal of Hepatology. 68 (2018) - p. S278 , 2018

Link: https://doi.org/10.1016/..

4

Cirrhosis, high age and high body mass index are risk facto..:

Hedenstierna, M. ; Nangarhari, A. ; El‐Sabini, A...
Journal of Viral Hepatitis. 25 (2018) 7 - p. 802-810 , 2018

Link: https://doi.org/10.1111/..

5

Retreatment of patients who failed glecaprevir/pibrentasvir..:

Wyles, D. ; Weiland, O. ; Yao, B....
Journal of Hepatology. 68 (2018) - p. S23-S24 , 2018

Link: https://doi.org/10.1016/..

6

Introduction of the second-generation direct-acting antivir..:

Frisk, P. ; Aggefors, K. ; Cars, T....
European Journal of Clinical Pharmacology. 74 (2018) 7 - p. 971-978 , 2018

Link: https://doi.org/10.1007/..

7

Long-term fibrosis improvement after sustained virologic re..:

Hedenstierna, M. ; Nangarhari, A. ; Weiland, O..
Journal of Hepatology. 66 (2017) 1 - p. S493-S494 , 2017

Link: https://doi.org/10.1016/..

8

Safety of glecaprevir/pibrentasvir in adults with chronic g..:

Dufour, J.-F. ; Zuckerman, E. ; Zadeikis, N....
Journal of Hepatology. 66 (2017) 1 - p. S515 , 2017

Link: https://doi.org/10.1016/..

9

The Effect of Sofosbuvir Containing Regimes in Patients wit..:

Dalgard, O. ; Weiland, O. ; Noraberg, G....
Journal of Hepatology. 64 (2016) 2 - p. S803 , 2016

Link: https://doi.org/10.1016/..

10

Daclatasvir plus Sofosbuvir with or without Ribavirin for t..:

Petersen, J. ; Welzel, T. ; Herzer, K....
Journal of Hepatology. 64 (2016) 2 - p. S781-S782 , 2016

Link: https://doi.org/10.1016/..

11

Daclatasvir plus Sofosbuvir with or without Ribavirin for T..:

Welzel, T. ; Petersen, J. ; Herzer, K....
Journal of Hepatology. 64 (2016) 2 - p. S825 , 2016

Link: https://doi.org/10.1016/..

12

Effectiveness of Daclatasvir Based Therapy in Patients with..:

Weis, N. ; Young, J. ; Hofer, H....
Journal of Hepatology. 64 (2016) 2 - p. S801 , 2016

Link: https://doi.org/10.1016/..

13

The Presence of Diabetes Mellitus is a Strong Risk Factor f..:

Hedenstierna, M. ; Nangarhari, A. ; Weiland, O..
Journal of Hepatology. 64 (2016) 2 - p. S620 , 2016

Link: https://doi.org/10.1016/..

14

Long-term follow-up of successful hepatitis C virus therapy..:

Hedenstierna, M. ; Weiland, O. ; Brass, A....
Alimentary Pharmacology & Therapeutics. 41 (2015) 6 - p. 532-543 , 2015

Link: https://doi.org/10.1111/..

15

LP49 : Sofosbuvir containing regimes to patients with HCV g..:

Dalgard, O. ; Weis, N. ; Noraberg, G....
Journal of Hepatology. 62 (2015) - p. S287-S288 , 2015

Link: https://doi.org/10.1016/..